mRNA疗法市场依技术平台、治疗应用及给药方式划分－2025-2032年全球预测

预计到 2032 年，mRNA 疗法市场规模将达到 2,571.1 亿美元，复合年增长率为 25.41%。

主要市场统计数据
基准年 2024	419.9亿美元
预计年份：2025年	525.9亿美元
预测年份：2032年	2571.1亿美元
复合年增长率 (%)	25.41%

mRNA疗法迎来了一个具有里程碑意义的时刻，科学突破、生产规模化需求和监管发展在此交汇融合，重塑了研发重点。

mRNA疗法领域目前正处于科学检验、生产规模化和法律规范不断演进的交汇点，这为研发人员、投资者和医疗监管机构创造了一个独特的曲折点。核心平台技术的进步表明，递送编码的治疗有效载荷可以引发持续且可控的生物反应，而製剂科学和低温运输物流的改进则降低了以往临床应用的障碍。随着计划从概念验证进入后期开发阶段，相关人员临着日益复杂的决策，涵盖平台选择、给药途径和特定治疗的安全性评估等面向。

在此背景下，产业必须协调快速的技术进步与商业性执行的现实。投资重点正从纯粹的研发活动转向建构生产能力、品质保证和监管准备。同时，免疫学家、製剂科学家和製程工程师之间的跨领域合作对于加快研发进程和降低临床风险至关重要。新监管指南的出台和与支付方的讨论进一步凸显了整合策略的必要性。当前环境有利于那些能够将技术差异化、可重复的临床结果和永续供应链结合的企业。

平台成熟、製造现代化、监管协调和递送途径优化正在共同重塑 mRNA 疗法的临床和商业策略。

近期趋势正在发生变革性变化，重新定义mRNA疗法的研发、生产和递送方式。平台演进是其中最重要的变化之一，脂质奈米颗粒化学和替代载体系统的最佳化显着改善了生物分布和耐受性。这项进步使得mRNA疗法的应用范围从疫苗扩展到慢性病和罕见疾病领域，从而拓展了治疗前景。同时，生产技术的进步——例如连续生产、一次性系统和模组化设施设计——缩短了製程转移前置作业时间，并提高了多产品生产工厂的灵活性。这些营运方面的改进降低了临床批次规模化的门槛，并支持了更有效率的产品开发週期。

监管路径也从临时性的、针对特定适应症的指导方针，演变为更标准化的框架，以认可平台间的相似性。这些监管趋势鼓励申办方设计利用平台资料包的研发项目，从而简化后续的产品申报流程。肌肉注射、静脉注射和皮下注射等给药途径正日益并行优化，以满足不同的治疗目标，这影响製剂、给药策略和以患者为中心的考量。最后，商业模式也正在适应小型创新者与大型製造商之间合作日益普遍的现状，使敏捷的科学能够获得所需的生产能力和市场推广经验，从而惠及更多患者。

美国2025年关税政策的最新变化将如何影响mRNA疗法研发的供应链架构、筹资策略和製造地选择？

2025年美国关税措施的累积影响将为mRNA治疗供应链中的企业带来一系列营运和策略的考量。关税变化正在影响筹资策略，尤其是对脂质、核苷酸和特殊辅料等关键上游原料的采购，迫使企业团队重新评估其供应商布局和库存缓衝。为此，许多公司正在实现供应商多元化，降低对单一国家的风险敞口，同时加快对贸易安排更为有利的国家和地区的替代供应商进行资格认证。这些措施正在重塑采购流程，并使供应商审核和品质监管变得更加复杂。

进口关税的变化也影响物流和製造业的经济效益，改变了关键零件和成品的到岸成本。这导致企业重新调整短期采购重点，转而倾向于签订长期合同，并对供应受限的特种材料进行策略性储备。企业也正在重新评估其生产布局，考虑跨多个贸易区转移或扩大产能所涉及的成本和监管週期。同时，製造商也在重新评估其合约策略，包括与合约开发和製造组织签订长期服务协议，以锁定产能并减轻关税制度变化带来的营运波动。

最后，关税环境凸显了政策资讯在商业规划中的重要性。研发团队和企业领导者正与贸易和法律专家更紧密合作，模拟各种情境对成本结构和进度安排的影响。这种合作使企业能够将关税敏感性分析纳入研发和供应连续性计划，确保研发里程碑能够应对外部贸易政策的变化。

策略性細項分析揭示了平台选择、治疗重点和给药方式如何共同决定开发路径和营运需求。

细分市场动态分析揭示了平台选择、治疗标靶和递送方法如何相互作用，从而决定专案层面的策略和商业性管道。在考虑技术平台差异化时，脂质奈米颗粒已成为一种用途广泛且应用广泛的载体系统，支援全身和局部递送。基于聚合物的平台因其可自订的释放动力学和模组化化学结构而备受关注，这些特性可以解决稳定性方面的限制。这些平台选择使申办方能够根据其生物作用机制和生产能力来选择合适的平台。

按治疗用途进行细分可以进一步优化策略选择。在心血管适应症方面，研发人员优先考虑给药途径和製剂稳定性，以优化组织标靶性和重复给药的耐受性。在感染疾病，研发管道通常着重于免疫抗原性特征和快速规模化生产，以应对疫情爆发。同时，罕见疾病通常需要量身定制的研发计划，强调小规模生产、高效价製剂和以患者为中心的给药方案。这些治疗方法的差异也导致了不同的风险接受度、临床试验设计和商业化合作伙伴。

肌肉注射给药支持分散给药和广泛的免疫宣传活动，静脉注射可实现复杂适应症的全身生物分布，而皮下注射给药则为慢性治疗提供了更便捷的给药方式。选择合适的给药途径需要综合考虑临床目标、患者体验和供应链实际情况。平台、应用和给药方式之间的相互作用决定了计画时间表、临床终点的选择以及确保计画顺利实施所需的生产能力。

全球各地区域政策、製造业生态系统和法规的差异，影响研发顺序和供应链连续性策略。

区域动态在塑造mRNA疗法的研发重点、监管环境和商业化策略方面发挥着至关重要的作用。在美洲，市场参与者必须适应一个以先进的临床网络、活跃的风险投资和私募股权活动以及不断完善指导方针以适应伙伴关係型应用为特征的监管相关人员构成的生态系统。这些特点为加速后期临床试验、临床检验和与支付方洽谈的合作创造了沃土。该地区还拥有丰富的受託製造和开发服务生态系统，使申办方能够在无需资本密集型设施扩建的情况下扩大生产规模。

在欧洲、中东和非洲，不同司法管辖区的监管差异以及区域性卫生技术评估框架的存在，影响产品上市顺序和证据产生的优先顺序。在该地区营运的公司通常会透过集中提交监管文件（如适用）并根据各国报销政策的细微差别调整策略，来规划其临床项目。此外，该地区也为与支持转化和比较疗效研究的学术中心和联盟开展合作提供了机会。在亚太地区，市场动态呈现出多元化的特点，包括政府主导的强有力的生产计划、快速发展的临床试验能力以及对生物製造能力本土化的关注。这些市场的政策制定者越来越支持对生物技术和先进疗法的投资，从而奖励本地化生产和区域化供应链策略。

在所有地区，跨境合作仍然是推动复杂专案的关键槓桿。跨区域的监管互动、生产伙伴关係和临床试验中心网路对于缩短研发週期和确保供应连续性至关重要。因此，有效的区域策略应在检验全球平台的同时，针对每个区域制定量身定制的监管和商业性策略。

竞争格局表明，创新主导的合作、垂直製造整合和策略伙伴关係正在加速实验室成果向临床转化。

mRNA疗法领域的竞争格局反映了科学差异化、合作模式和垂直整合策略的融合。创新者优先考虑平台新颖性和临床差异化，以确保有利的合作和许可协议；而现有生物製药公司则通常透过收购或策略联盟来快速获取关键技术平台。合约研发受託製造公司则透过拓展製剂、无菌灌装、低温运输物流等方面的能力来应对竞争，从而将自身定位为扩大临床项目规模和支持商业化上市的重要合作伙伴。

各公司投资组合中呈现出几种反覆出现的策略模式。首先，拥有强大平台智慧财产权和可靠临床前证据的公司正利用选择性合作关係来加速转化活动，同时又不牺牲长期价值。其次，专注于慢性病应用的公司正在投资差异化的给药方式和製剂，以实现重复给药并提高患者依从性。第三，瞄准肿瘤和罕见疾病计画的公司正在与专业临床网路和病患权益组织建立更紧密的联繫，以指导临床试验设计并加速病患招募。最后，专业製造公司和服务供应商正透过提供端到端的整合解决方案来提升自身竞争优势，创造价值提案，从而减轻临床试验赞助者的协调负担并缩短生产规模化週期。

为高阶主管提供实际可行的高影响力建议，以加速研发进度、增强供应连续性，并使证据产生与支付方预期保持一致。

产业领导者可以采取一系列切实可行的措施来应对技术复杂性和商业性不确定性，同时加速专案成功。优先考虑与平台无关的开发管道，能够帮助企业在分析、对比测试和监管沟通方面提升跨专案的效率。早期投资于製剂和给药优化可以降低下游临床风险，并提高患者接受度，尤其对于需要重复给药的适应症。企业还应将供应连续性计画纳入开发时间表，在关键测试开始前充分验证备用供应商和紧急生产安排，以减轻贸易和物流中断对营运的影响。

从市场准入的角度来看，与契约製造和临床网路建立策略伙伴关係，无需大量前期投资即可释放产能并加快註册流程。领导者还应建立监管情报机制，以追踪不断变化的指导意见，并针对不同适应症创建模组化、可重复使用的附加檔要素。商业团队应儘早与支付者和卫生技术评估机构接洽，制定能够展现超越传统临床终点价值的证据产生策略。最后，促进研发、生产、监管事务和商业规划之间的跨职能管治，可以加快决策速度，确保科学进步转化为可行的上市计划和可持续的产品生命週期。

采用严谨的多源研究途径，结合专家访谈、监管审查、技术文献综述和情境分析，挖掘出可操作的行业考察。

本分析的研究结合了定性专家访谈、公开监管文件审查以及对近期科学文献的跨领域综合分析，从而全面展现了mRNA疗法生态系统。研究人员与科学家、製程工程师、监管顾问、生产主管和商业策略师进行了专家对话，以了解营运情况并识别新兴的最佳实践。研究人员还查阅了监管材料和指导文件，以提供符合当前平台申报和生产可比性评估要求的见解。此外，研究人员还查阅了科学出版物和会议论文集，以了解载体化学、递送管道和製剂稳定性数据的最新进展。

调查方法着重于三角验证，检验定性输入与同期政策变化和技术公告进行比对，以减少偏差并揭示稳健的趋势。对代表性研发项目的案例分析提供了详细信息，阐明了平台选择、给药途径和治疗靶点如何带来不同的风险和运营状况。供应链情境规划和关税敏感性分析也被纳入考量，以评估外部政策和物流因素如何影响专案的可行性。研究始终优先考虑与决策者相关的可操作性见解，重点关注对临床设计、生产策略、监管互动和商业计划的实际影响。

最后，我们整合了科学、营运和政策动态，这将决定哪些组织能够将 mRNA 创新转化为持续的临床和商业性成功。

mRNA治疗领域呈现出快速的技术进步、不断变化的运作模式和持续演进的政策环境，这些因素共同带来了巨大的机会和复杂的挑战。载体技术的进步、生产製造的现代化以及递送管道的最佳化，正在拓展mRNA治疗的应用范围；而监管和贸易的发展则要求更精细的风险管理和策略规划。在这种环境下，能够将卓越的科学研究实力与务实的供应链设计、稳健的监管策略以及早期与支付方的沟通相结合的机构，将更有机会取得成功。将敏捷的创新者与成熟的生产和商业化合作伙伴结合的协作模式，有望加速成果转换并降低执行风险。

总之，推进这项工作需要采取平衡的方法，使平台和交付方式的选择与临床目标保持一致，预见供应和政策方面的阻力，并建立跨职能能力，将洞见转化为可执行的专案。积极应对这些方面的机构将更有能力将科学前景转化为持续的治疗和商业性成果。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 设计新型脂质奈米颗粒载体以增强组织特异性mRNA递送
• 整合自扩增mRNA平台可降低给药频率和成本。
• 基于mRNA的癌症疫苗加速核准的监管途径正在不断发展。
• 生技公司与学术界合作开发针对罕见疾病的个人化mRNA疗法
• 开发可提高体内稳定性和翻译效率的DNA/mRNA杂合结构
• 寻找新型佐剂以增强预防性mRNA免疫疗法中的免疫反应
• 扩大连续生产製程规模，实现经济高效的大规模mRNA生产
• 透过创新冻干技术，推动低温运输物流发展，以促进mRNA疫苗的分发

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依技术平台分類的mRNA疗法市场

• 脂质奈米颗粒
• 聚合物基
• 病毒载体

第九章 mRNA疗法市场：依治疗应用划分

• 心血管系统
• 感染疾病
• 肿瘤学
• 罕见疾病

第十章 mRNA疗法市场：依给药方式划分

• 肌肉内注射
• 静脉
• 皮下

第十一章 mRNA疗法市场（按地区划分）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十二章 mRNA疗法市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十三章 各国mRNA疗法市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十四章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Moderna, Inc.
  • BioNTech SE
  • CureVac NV
  • Sanofi SA
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Arcturus Therapeutics Holdings, Inc.
  • Providence Therapeutics Holdings Inc.
  • Ethris GmbH
  • eTheRNA immunotherapies NV

The mRNA Therapeutics Market is projected to grow by USD 257.11 billion at a CAGR of 25.41% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 41.99 billion
Estimated Year [2025]	USD 52.59 billion
Forecast Year [2032]	USD 257.11 billion
CAGR (%)	25.41%

A critical juncture in mRNA therapeutics where scientific breakthroughs, manufacturing scale demands, and regulatory developments converge to reshape development priorities

The field of mRNA therapeutics is now at the intersection of scientific validation, manufacturing scale-up, and evolving regulatory frameworks, creating a unique inflection point for developers, investors, and health authorities. Advances in core platform technologies have demonstrated that encoded delivery of therapeutic payloads can trigger durable and controllable biological responses, while parallel improvements in formulation science and cold-chain logistics have reduced historical barriers to clinical translation. As projects move from proof-of-concept to later-stage development, stakeholders face an increasingly complex set of decisions spanning platform selection, delivery routes, and therapy-specific safety profiles.

Against this backdrop, the industry must reconcile rapid technological progress with the practicalities of commercial execution. Investment priorities are shifting from purely discovery-focused activities to buildouts in manufacturing capacity, quality assurance, and regulatory readiness. Meanwhile, cross-disciplinary collaboration between immunologists, formulation scientists, and process engineers is becoming essential to accelerate timelines and mitigate clinical risk. The introduction of new regulatory guidances and payer discussions further underscores the need for integrated strategies that combine scientific rigor with pragmatic commercialization planning. Ultimately, the current environment rewards organizations that can translate technical differentiation into reproducible clinical outcomes and sustainable supply chains.

Platform maturation, manufacturing modernization, regulatory harmonization, and delivery route optimization are collectively remaking clinical and commercial strategies in mRNA therapeutics

Recent years have witnessed transformative shifts that are redefining how mRNA therapeutics are developed, manufactured, and delivered. Platform evolution is one of the most consequential shifts, as optimizations in lipid nanoparticle chemistry and alternative carrier systems have materially improved biodistribution and tolerability profiles. This progress has, in turn, enabled broader therapeutic ambitions beyond vaccine applications into chronic and rare disease indications. Simultaneously, advances in manufacturing technologies-continuous processing, single-use systems, and modular facility designs-have reduced lead times for process transfer and increased flexibility for multi-product plants. These operational improvements lower the threshold for scaling clinical batches and support more iterative product development cycles.

Regulatory pathways are also evolving from ad hoc, indication-specific guidance toward more standardized frameworks that recognize platform-based similarities. These regulatory trends are encouraging sponsors to design development programs that leverage platform data packages to streamline subsequent product filings. Another major shift is the growing emphasis on delivery modality; intramuscular, intravenous, and subcutaneous routes are now being optimized in parallel for distinct therapeutic goals, which has implications for formulation, dosing strategies, and patient-centric considerations. Finally, commercial models are adapting to a landscape where partnerships between small innovators and large-scale manufacturers are increasingly commonplace, enabling nimble science to access the production capacity and market access expertise necessary for broader patient reach.

How recent United States tariff shifts in 2025 are reshaping supply chain architecture, procurement strategies, and manufacturing footprint decisions across mRNA therapeutic development

The cumulative impact of the United States tariff policy developments in 2025 introduces a series of operational and strategic considerations for organizations involved in the mRNA therapeutics supply chain. Tariff changes have influenced sourcing strategies for key upstream inputs, particularly lipids, nucleotides, and specialized excipients, causing teams to re-evaluate supplier footprints and inventory buffers. In response, many organizations have initiated supplier diversification efforts to reduce single-country exposure, while others have accelerated qualification of alternative vendors in jurisdictions with more favorable trade arrangements. These efforts are reshaping procurement timelines and adding complexity to supplier audits and quality oversight.

Logistics and manufacturing economics have also been affected, as changes in import duties alter landed costs for critical components and finished goods. The result is a recalibration of near-term procurement priorities, with increased emphasis on long-lead contracts and strategic stockpiling for materials that are both specialized and supply-constrained. Companies are also reassessing their manufacturing footprints, weighing the costs and regulatory time associated with relocating or expanding production capacity in multiple trade zones. In parallel, manufacturers are rethinking contracting strategies, including longer-term service agreements with contract development and manufacturing organizations to lock in capacity and mitigate the operational variability introduced by shifting tariff regimes.

Finally, the tariff environment has underscored the importance of policy intelligence as part of commercial planning. Development teams and business leaders are collaborating more closely with trade and legal experts to model scenario impacts on cost structures and timelines. This alignment is prompting organizations to incorporate tariff sensitivity analyses into their go-to-market and supply continuity plans, ensuring that development milestones remain resilient to external trade policy changes.

Strategic segmentation analysis revealing how platform choices, therapeutic target priorities, and delivery modalities jointly determine development paths and operational needs

Insight into segmentation dynamics reveals how platform choices, therapeutic targets, and delivery methods interact to define program-level strategies and commercial pathways. When considering technology platform differentiation, lipid nanoparticles have emerged as a versatile and widely adopted carrier system that supports systemic and local delivery ambitions; polymer-based platforms are attracting interest for tailored release kinetics and modular chemistry that can address stability constraints; viral vectors continue to be explored for applications where high transduction efficiency is essential, particularly when long-term expression or cell-specific targeting is required. Together, these platform options compel sponsors to align platform selection with the biological mechanism of action and manufacturing capabilities.

Therapeutic application segmentation further refines strategic choices. For cardiovascular indications, developers prioritize delivery routes and formulation stability that optimize tissue targeting and repeat dosing tolerability. In infectious diseases, development pathways often emphasize immunogenicity profiles and rapid scalability to address outbreak scenarios. Oncology programs center on tumor targeting, dosing intensity, and combination strategies with existing modalities, while rare diseases frequently demand bespoke development plans that emphasize small-batch manufacturing, high-potency formulation, and patient-centered administration modalities. These therapeutic distinctions drive different risk tolerances, clinical trial designs, and commercialization partners.

Delivery method segmentation is equally consequential, as intramuscular administration supports decentralized delivery and broad immunization campaigns, intravenous approaches enable systemic biodistribution for complex indications, and subcutaneous routes offer patient-friendly dosing possibilities for chronic therapies. Selecting the appropriate delivery modality requires integrating clinical goals, patient experience considerations, and supply-chain realities, since each route carries distinct formulation and stability requirements. The interplay among platform, application, and delivery modality shapes program timelines, clinical endpoint selection, and the types of manufacturing competencies required to execute reliably.

Regional policy, manufacturing ecosystems, and regulatory variability across global territories that shape development sequencing and supply continuity strategies

Regional dynamics play a decisive role in shaping R&D priorities, regulatory pathways, and commercialization strategies across the mRNA therapeutics landscape. In the Americas, market actors must navigate an ecosystem characterized by advanced clinical networks, strong venture and private-equity activity, and regulatory agencies that are refining guidance to accommodate platform-based submissions. These features create fertile ground for late-stage trials and partnerships that can accelerate clinical validation and payer discussions. The region also features a dense contract manufacturing and development services ecosystem, offering sponsors multiple pathways to scale production without immediate capital-intensive facility expansion.

In Europe, Middle East & Africa, regulatory heterogeneity across jurisdictions and the presence of regional health technology assessment frameworks influence go-to-market sequencing and evidence generation priorities. Companies operating in this region often map clinical programs to achieve both centralized regulatory filings where appropriate and tailored national strategies to address reimbursement nuances. Additionally, the region presents collaboration opportunities with academic centers and consortiums that can support translational research and comparative effectiveness studies. In Asia-Pacific, diverse market dynamics include strong government-led manufacturing initiatives, rapidly scaling clinical trial capacity, and interest in domesticizing biomanufacturing capabilities. Policymakers across these markets are increasingly supportive of biotech and advanced therapy investments, creating incentives for local production and regionally focused supply chain strategies.

Across all regions, cross-border collaboration remains a key enabler for advancing complex programs. Regulatory dialogue, manufacturing partnerships, and clinical site networks that span multiple geographies are instrumental for accelerating development timelines and ensuring supply continuity. Effective regional strategies therefore balance global platform validation with locally tailored regulatory and commercial approaches.

Competitive patterns showing innovation-led alliances, vertical integration in manufacturing, and strategic partnerships that accelerate translation from lab to clinic

Competitive behavior in the mRNA therapeutics space reflects a mix of scientific differentiation, partnership models, and vertical integration strategies. Innovators prioritize platform novelty and clinical differentiation to secure advantageous partnering or licensing agreements, while established biopharma players typically pursue acquisition or strategic collaboration to gain rapid access to leading technology platforms. Contract development and manufacturing organizations are responding by expanding capabilities across formulation, aseptic fill-finish, and cold-chain logistics, positioning themselves as essential partners for scaling clinical programs and supporting commercial launches.

Across corporate portfolios, several recurring strategic patterns emerge. First, companies with strong platform IP and robust preclinical evidence are leveraging selective alliances to accelerate translational activities without relinquishing long-term value. Second, organizations focused on chronic disease applications are investing in delivery and formulation differentiation to enable repeated dosing and improve patient adherence. Third, firms targeting oncology and rare disease programs are building close relationships with specialized clinical networks and patient advocacy groups to inform trial design and accelerate enrollment. Finally, manufacturing-focused firms and service providers are carving out competitive moats by offering integrated end-to-end solutions, creating value propositions that reduce the coordination burden for sponsors and compressed timelines for production scale-up.

Practical, high-impact recommendations for executives to accelerate development timelines, strengthen supply continuity, and align evidence generation with payer expectations

Industry leaders can adopt a set of actionable practices to navigate technological complexity and commercial uncertainty while accelerating program success. Prioritizing platform-agnostic development pathways allows organizations to capture cross-program efficiencies in analytics, comparability studies, and regulatory engagements. Investing early in formulation and delivery optimization reduces downstream clinical risk and improves patient acceptability, particularly for indications that require repeat dosing. Companies should also embed supply continuity planning into their development timelines, validating secondary suppliers and contingency manufacturing arrangements well before pivotal studies begin, which mitigates the operational impact of trade or logistics disruptions.

From a go-to-market perspective, establishing strategic partnerships with contract manufacturers and clinical networks can unlock capacity and expedite enrollment without large upfront capital commitments. Leaders should also institutionalize regulatory intelligence functions to track evolving guidances and create modular dossier elements that can be repurposed across indications. Commercial teams must engage with payers and health technology assessors early to shape evidence generation strategies that demonstrate value beyond traditional clinical endpoints. Finally, cultivating cross-functional governance that aligns R&D, manufacturing, regulatory affairs, and commercial planning will accelerate decision-making and ensure that scientific advances translate into executable launch plans and sustainable product lifecycles.

A rigorous, multi-source research approach combining expert interviews, regulatory review, technical literature synthesis, and scenario analysis to surface actionable industry insights

The research underpinning this analysis combined qualitative expert interviews, public regulatory documentation reviews, and cross-disciplinary synthesis of recent scientific literature to ensure a comprehensive view of the mRNA therapeutics ecosystem. Expert conversations were conducted with scientists, process engineers, regulatory advisors, manufacturing executives, and commercial strategists to capture operational realities and identify emergent best practices. Regulatory source materials and guidance documents were examined to align insights with current expectations for platform-based submissions and manufacturing comparability assessments. Scientific publications and conference proceedings were reviewed to capture the latest advances in carrier chemistry, delivery routes, and formulation stability data.

The methodology emphasized triangulation: qualitative inputs were cross-validated against contemporaneous policy shifts and technical publications to reduce bias and surface robust trends. Case-level analyses of representative development programs provided granularity on how platform choice, delivery route, and therapeutic target drive different risk and operational profiles. Supply chain scenario planning and tariff sensitivity reviews were integrated to assess how external policy and logistics factors influence program viability. Throughout, the approach prioritized actionable insights relevant to decision-makers, focusing on practical implications for clinical design, manufacturing strategy, regulatory interactions, and commercial planning.

Final synthesis of scientific, operational, and policy dynamics that determine which organizations will convert mRNA innovation into durable clinical and commercial success

The mRNA therapeutics landscape is characterized by rapid technical progress, shifting operational paradigms, and evolving policy environments that together present both significant opportunities and complex challenges. Progress in carrier technologies, manufacturing modernization, and delivery route optimization has expanded the range of feasible therapeutic applications, while regulatory and trade developments require more sophisticated risk management and strategic planning. Success in this environment will favor organizations that integrate scientific excellence with pragmatic supply chain design, robust regulatory strategies, and early payer engagement. Collaborative approaches that pair nimble innovators with established manufacturing or commercialization partners are likely to accelerate translation and reduce executional risk.

In conclusion, the path forward requires a balanced approach that aligns platform and delivery selection with clinical objectives, anticipates supply and policy headwinds, and builds cross-functional capabilities to translate insights into deliverable programs. Organizations that proactively address these dimensions will be better positioned to convert scientific promise into durable therapeutic and commercial outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Engineering novel lipid nanoparticle vectors to enhance tissue-specific mRNA delivery
• 5.2. Integration of self-amplifying mRNA platforms to lower dosing frequency and costs
• 5.3. Regulatory pathways evolving for accelerated approval of mRNA-based cancer vaccines
• 5.4. Collaborations between biotech firms and academia to develop personalized mRNA therapeutics for rare diseases
• 5.5. Development of hybrid DNA/mRNA constructs to improve stability and translation efficiency in vivo
• 5.6. Exploration of novel adjuvants to potentiate immune response in prophylactic mRNA immunotherapies
• 5.7. Scale-up of continuous manufacturing processes for cost-effective large-scale mRNA production
• 5.8. Addressing cold chain logistics by innovating lyophilization techniques for mRNA vaccine distribution

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. mRNA Therapeutics Market, by Technology Platform

• 8.1. Lipid Nanoparticles
• 8.2. Polymer Based
• 8.3. Viral Vectors

9. mRNA Therapeutics Market, by Therapeutic Application

• 9.1. Cardiovascular
• 9.2. Infectious Diseases
• 9.3. Oncology
• 9.4. Rare Diseases

10. mRNA Therapeutics Market, by Delivery Method

• 10.1. Intramuscular
• 10.2. Intravenous
• 10.3. Subcutaneous

11. mRNA Therapeutics Market, by Region

• 11.1. Americas
  • 11.1.1. North America
  • 11.1.2. Latin America
• 11.2. Europe, Middle East & Africa
  • 11.2.1. Europe
  • 11.2.2. Middle East
  • 11.2.3. Africa
• 11.3. Asia-Pacific

12. mRNA Therapeutics Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. mRNA Therapeutics Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Analysis
  • 14.3.1. Moderna, Inc.
  • 14.3.2. BioNTech SE
  • 14.3.3. CureVac N.V.
  • 14.3.4. Sanofi S.A.
  • 14.3.5. Pfizer Inc.
  • 14.3.6. GlaxoSmithKline plc
  • 14.3.7. Arcturus Therapeutics Holdings, Inc.
  • 14.3.8. Providence Therapeutics Holdings Inc.
  • 14.3.9. Ethris GmbH
  • 14.3.10. eTheRNA immunotherapies NV

LIST OF FIGURES

• FIGURE 1. GLOBAL MRNA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 9. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GCC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. BRICS MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. G7 MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. NATO MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. MRNA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 26. MRNA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. MRNA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL MRNA THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL MRNA THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY POLYMER BASED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY POLYMER BASED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY POLYMER BASED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY POLYMER BASED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY POLYMER BASED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY POLYMER BASED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 73. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 74. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 75. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 76. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 77. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 78. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 79. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 80. AMERICAS MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 81. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 82. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 83. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 84. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 85. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 86. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 87. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 88. NORTH AMERICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 89. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 92. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 93. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 94. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 95. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 96. LATIN AMERICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 97. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 98. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 99. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 105. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 108. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 109. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 110. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 111. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 112. EUROPE MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 113. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 115. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 116. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 117. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 118. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 119. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 120. MIDDLE EAST MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 121. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 124. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 125. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 126. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 127. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 128. AFRICA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 129. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 132. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 133. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 134. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 135. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 136. ASIA-PACIFIC MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 139. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 142. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 143. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 144. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 145. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 146. ASEAN MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 147. GCC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 148. GCC MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 149. GCC MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 150. GCC MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 151. GCC MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 152. GCC MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 153. GCC MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 154. GCC MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 155. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 158. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 159. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 160. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 161. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 162. EUROPEAN UNION MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 163. BRICS MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 164. BRICS MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 165. BRICS MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 166. BRICS MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 167. BRICS MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 168. BRICS MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 169. BRICS MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 170. BRICS MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 171. G7 MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 172. G7 MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 173. G7 MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 174. G7 MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 175. G7 MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 176. G7 MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 177. G7 MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 178. G7 MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 179. NATO MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. NATO MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. NATO MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 182. NATO MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 183. NATO MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 184. NATO MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 185. NATO MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 186. NATO MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL MRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 189. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 190. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 191. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 192. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 193. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 194. UNITED STATES MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 195. CANADA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 196. CANADA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 197. CANADA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 198. CANADA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 199. CANADA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 200. CANADA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 201. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 202. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 203. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 204. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 205. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 206. MEXICO MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 207. BRAZIL MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 208. BRAZIL MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 209. BRAZIL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 210. BRAZIL MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 211. BRAZIL MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 212. BRAZIL MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 213. UNITED KINGDOM MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 214. UNITED KINGDOM MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 215. UNITED KINGDOM MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 216. UNITED KINGDOM MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 217. UNITED KINGDOM MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 218. UNITED KINGDOM MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 219. GERMANY MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 220. GERMANY MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 221. GERMANY MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 222. GERMANY MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 223. GERMANY MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 224. GERMANY MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 225. FRANCE MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 226. FRANCE MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 227. FRANCE MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 228. FRANCE MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 229. FRANCE MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 230. FRANCE MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 231. RUSSIA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 232. RUSSIA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 233. RUSSIA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 234. RUSSIA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 235. RUSSIA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 236. RUSSIA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 237. ITALY MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 238. ITALY MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 239. ITALY MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 240. ITALY MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 241. ITALY MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 242. ITALY MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 243. SPAIN MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 244. SPAIN MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 245. SPAIN MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 246. SPAIN MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 247. SPAIN MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 248. SPAIN MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 249. CHINA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 250. CHINA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 251. CHINA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 252. CHINA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 253. CHINA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 254. CHINA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 255. INDIA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 256. INDIA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 257. INDIA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 258. INDIA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 259. INDIA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 260. INDIA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 261. JAPAN MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 262. JAPAN MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 263. JAPAN MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 264. JAPAN MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 265. JAPAN MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 266. JAPAN MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 267. AUSTRALIA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 268. AUSTRALIA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 269. AUSTRALIA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 270. AUSTRALIA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 271. AUSTRALIA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 272. AUSTRALIA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 273. SOUTH KOREA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
• TABLE 274. SOUTH KOREA MRNA THERAPEUTICS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
• TABLE 275. SOUTH KOREA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2024 (USD MILLION)
• TABLE 276. SOUTH KOREA MRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025-2032 (USD MILLION)
• TABLE 277. SOUTH KOREA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 278. SOUTH KOREA MRNA THERAPEUTICS MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 279. MRNA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 280. MRNA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024